Prosjektet undersøker effekten av ulike medikamenter som blokkerer sentrale metabolske signalveier i akutt myeloid leukemi (AML). Prosjektet har som mål å karakterisere ulike metabolske signalveier i leukemiceller, samt autofagi, og studere hvordan dette bidrar til kjemoresistens i AML. Prosjektet er støttet av midler fra Bergens forskningsstiftelse.

2026

• Marte Karen Brattås; Kimberley Joanne Hatfield; Kristin Paulsen Rye et al. (2026). Metabolomics profiling of acute myelogenous leukemia patients to identify systemic differences associated with in vitro sensitivity to SYK inhibitors. (ekstern lenke)

2012

• Håkon Reikvam; Kimberley Joanne Hatfield; Hanne Kristin Fredly et al. (2012). The angioregulatory cytokine network in human acute myeloid leukemia - from leukemogenesis via remission induction to stem cell transplantation. (ekstern lenke)
• Øystein Bruserud; Håkon Reikvam; Astrid Marta Olsnes Kittang et al. (2012). High-dose etoposide in allogeneic stem cell transplantation. (ekstern lenke)

2009

• Håkon Reikvam; Kimberley Joanne Hatfield; Anne Margrete Øyan et al. (2009). Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors; release profile and pharmacological modulaion. (ekstern lenke)

2010

• Kimberley Joanne Hatfield; Siv Lise Bedringaas; Anita Ryningen et al. (2010). Hypoxia increases HIF-1 alpha expression and constitutive cytokine release by primary human acute myeloid leukaemia cells. (ekstern lenke)

2022

• Kimberley Joanne Hatfield; Øystein Bruserud; Håkon Reikvam (2022). Pretransplant Systemic Lipidomic Profiles in Allogeneic Stem Cell Transplant Recipients. (ekstern lenke)

2015

• Håkon Reikvam; Annette Brenner; Karen Marie Hagen et al. (2015). The cytokine-mediated crosstalk between primary human acute myeloid cells and mesenchymal stem cells alters the local cytokine network and the global gene expression profile of the mesenchymal cells. (ekstern lenke)

2016

• Michelle Victoria Hauge; Øystein Bruserud; Kimberley Joanne Hatfield (2016). Targeting of cell metabolism in human acute myeloid leukemia - more than targeting of isocitrate dehydrogenase mutations and PI3K/AKT/mTOR signaling?. (ekstern lenke)

2025

• Marte Karen Brattås; Franziska Stilla Maria Görtler; Silje Johansen et al. (2025). Gene Expression Profiling in Acute Myeloid Leukemia Patient Subgroups With High and Low Sensitivity Toward SYK Inhibitors. (ekstern lenke)

2018

• Ina Nepstad; Kimberley Joanne Hatfield; Elise Aasebø et al. (2018). Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic and transcriptomic comparison. (ekstern lenke)

Se en fullstendig oversikt over publikasjoner i NVA.

2016-2020: Metabolic phenotypes of leukemia cells.